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Abstract—The renin-angiotensin system is a powerful regulator of arterial pressure and body fluid volume. Increasing evidence
suggests that the angiotensin type 2 receptor (AT2R), which mediates the vasodilatory and natriuretic actions of angiotensin
peptides, is enhanced in females and may, therefore, represent an innovative therapeutic target. We investigated the therapeutic
potential of direct AT2R stimulation on renal function in 11- to 12-week–old anesthetized male and female Sprague-Dawley
rats. Renal blood flow was examined in response to a graded infusion of the highly selective, nonpeptide AT2R agonist,
compound 21 (100, 200, and 300 ng/kg per minute), in the presence and absence of AT2R blockade (PD123319; 1 mg/kg per
hour). Direct AT2R stimulation significantly increased renal blood flow in both males and females, without influencing arterial
pressure. This was dose dependent in females only and occurred to a greater extent in females at the highest dose of compound
21 administered (males: 13.12.4% versus females: 23.03.2% change in renal blood flow at 300 ng/kg per minute versus
baseline; P0.01). In addition, AT2R stimulation significantly increased sodium and water excretion to a similar extent in
males and females (PGroup0.05 and 0.005). However, there was no significant change in glomerular filtration rate in either
sex, suggesting that altered tubular function may be responsible for AT2R-induced natriuresis rather than hemodynamic
effects. Taken together, this study provides evidence that direct AT2R stimulation produces vasodilatory and natriuretic effects
in the male and female kidney. The AT2R may, therefore, represent a valuable therapeutic target for the treatment of renal
and cardiovascular diseases in both men and women. (Hypertension. 2012;59[part 2]:409-414.)
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Before menopause, women are protected from hyperten-sion and cardiovascular disease relative to men. How-
ever, this protection weakens after menopause, and ultimately
the prevalence of hypertension in women exceeds that of
men.1 Alarmingly, sex-related differences have also been
reported in the efficacy of current cardiovascular therapies,2,3
with poorer treatment outcomes commonly reported in
women.3 The development of sex-specific approaches for the
treatment of hypertension and cardiovascular disease is,
therefore, of utmost importance.
It is well established that the kidney plays a central role in
arterial pressure control. The regulation of sodium excretion
by the kidney is critical to the long-term regulation of arterial
pressure given its influence on body fluid volume homeosta-
sis.4 In response to a rise in arterial pressure, sodium and
water excretion is increased to reduce extracellular fluid
volume and to restore arterial pressure to normal. Abnormal
renal excretory function is, therefore, recognized as a key
contributor to the development of hypertension.5
The renin-angiotensin system (RAS) plays a pivotal role in
the regulation of arterial pressure by the kidney because of its
influence on renal excretory function and vascular tone.4 The
majority of the classically recognized actions of angiotensin II
(Ang II) are mediated by the angiotensin type 1 receptor (AT1R),
including vasoconstriction, sodium reabsorption, and cell prolif-
eration.6 However, in recent years, a depressor axis of the RAS
has been discovered. In addition to Ang II, other biologically
active peptides derived from angiotensin I and Ang II directly
oppose the classic pressor actions of Ang II mediated by the
AT1R, by promoting vasodilation and natriuresis via their
interaction with the angiotensin type 2 receptor (AT2R).7
Accumulating evidence suggests that the vasodepressor
RAS pathways are enhanced in females. We, and others, have
identified major sex differences in the expression level of
various RAS components,8,9 together with differences in the
male and female response to RAS activation and inhibi-
tion.3,8,10,11 Of particular interest, increased AT2R expression
has been identified in the kidney and vasculature of female
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mice and rats compared with their male counterparts.8,12 In
both male and female rats, we recently identified a significant
role for the AT2R in the control of renal function. We
reported that the AT2R modulates sodium excretion in both
males and females to a similar extent. In addition, in females,
we identified a sex-specific role for the AT2R in the renal
vasculature, providing protection against the vasoconstrictor
effects of Ang II.13 Thus, increased renal expression of the
AT2R in females may underlie their cardiovascular protec-
tion, and, as such, therapeutic stimulation of the AT2R could
counterbalance the pressor actions of the RAS and may be a
suitable target for future cardiovascular treatments.
In this study we aimed to further define the sex-specific
role of the AT2R in the regulation of arterial pressure via the
modulation of renal hemodynamics and excretory function.
We examined the influence of direct AT2R stimulation on
renal function in male and female rats, using the highly
specific nonpeptide AT2R agonist, compound 21. We hypoth-
esized that direct AT2R stimulation would promote sodium
excretion and renal vasodilation to a greater extent in females.
Methods
Animals
Ten-week–old male and female Sprague-Dawley rats were obtained
from the Animal Resources Centre (Perth, Western Australia, Aus-
tralia) and were fed a sodium-controlled diet (0.25% sodium chlo-
ride; Specialty Feeds, Glen Forrest, Western Australia, Australia)
and water ad libitum. The rats were individually housed with a
12-hour light/dark cycle at a temperature of 21°C and were allowed
1 week to acclimatize. Experiments were approved by the Monash
University, School of Biomedical Sciences Animal Ethics Commit-
tee, and were performed in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes.
Surgical Procedure
The rats were prepared as described in detail previously.13 Briefly,
rats were anesthetized with Inactin (thiobutabarbital; 150 mg/kg;
Sigma Aldrich, St Louis, MO), and a tracheostomy was performed to
facilitate breathing. The left jugular vein and carotid artery were
catheterized for IV infusion of 2% BSA (Sigma Aldrich) and tritiated
inulin ([3H]inulin; Sigma Aldrich) and mean arterial pressure (MAP)
measurement, respectively. Next, the left kidney was exposed and
denervated and the left ureter was catheterized for urine collection.
Finally, a transit-time ultrasound flow probe (0.7VB; Transonic
Systems, Ithaca, NY) was placed around the renal artery for renal
blood flow (RBF) measurement.
Experimental Procedures
After surgery, PD123319 (1 mg/kg bolus plus 1 mg/kg per hour;
Sigma Aldrich) or vehicle (0.9% saline; 1 mL bolus plus 1 mL/h)
was administered intravenously for the duration of the experiment.
After 30 minutes, intravenous infusion of constant vehicle or graded
compound 21 (0, 100, 200, and 300 ng/kg per minute) commenced.
At each dose, after a 10-minute equilibration period, RBF measurements
were obtained for 5 minutes. Urine produced by the left kidney was
collected during the baseline and 300 ng/kg per minute collection
periods, and corresponding arterial blood samples were taken from the
left carotid artery at the period end. Urinary sodium concentrations were
measured as described previously,13 and fractional sodium excretion
(FENa) was calculated. Glomerular filtration rate was estimated based
on [3H]inulin clearance. At the end of the experiment the left kidney was
excised and weighed. The stage of the estrus cycle of each female rat
was also identified by a vaginal smear, and uterine weight was
measured. Compound 21 was provided by U.M.S. and T.U. (Charite´-
Universita¨tsmedizin Berlin, Berlin, Germany).
Statistical Analysis
Data are expressed as meanSEM. To compare differences in
physiological parameters and baseline values, data were analyzed
using an ANOVA with Tukey post hoc tests. MAP, RBF, and renal
vascular resistance (RVR) data were analyzed using repeated-
measures ANOVA with Bonferroni post hoc tests. To compare
differences in percentage changes in variables at 300 ng/kg per
minute compound 21 from baseline between treatment groups, data
were analyzed using a 2-way ANOVA. P values 0.05 were
considered statistically significant.
Results
Physiological Parameters
Both body weight (BW) and left kidney wet weight (KW)
were significantly greater in the male vehicle-treated (BW:
4279 g; left KW: 1.400.04 g), compound 21-treated (BW:
421.010.9 g; left KW: 1.500.05 g), and compound
21PD123319-treated (BW: 43812 g; left KW: 1.500.06
g) groups as compared with the female vehicle-treated (BW:
2637 g; left KW: 0.920.03 g), compound 21-treated (BW:
2719 g; left KW: 0.980.03 g), and compound
21PD123319-treated groups (BW: 2544 g; left KW:
0.880.02 g; PSex0.0001). Uterine weight did not differ
significantly between the female vehicle-treated (0.600.05 g),
compound 21-treated (0.550.04 g), and compound
21PD123319-treated (0.520.04 g) groups. Furthermore,
each female group consisted of both estrus and anestrus rats, in
equal proportion.
Influence of Direct AT2R Stimulation on
Renal Hemodynamics
There were no significant differences in basal MAP between
the male and female treatment groups (Table). In response to
the vehicle, graded compound 21 infusion, or graded com-
pound 21 infusion combined with PD123319, MAP remained
near baseline levels throughout the duration of the experiment
(Figure 1A and 1D). This response was similar between the
male and female treatment groups; however, there was a
small but significant (4 mm Hg) rise in MAP in the male
compound 21-treated group across the time course of the
experiment, as compared with the male compound
21PD123319-treated group (PGroup0.02).
In males, baseline RBF was similar among the 3 treatment
groups (Table). In response to vehicle infusion, there was no
significant change in RBF from the baseline level. In contrast,
RBF increased significantly in response to compound 21
infusion (PGroup0.0009; Figure 1B). At 300 ng/kg per
minute of compound 21, RBF was increased by 13.12.4%
as compared with baseline (P3000.001). This renal vasodi-
latory response to compound 21 in males was also evidenced
by reduced RVR, as compared with the male vehicle-treated
group (PGroup0.008; Figure 1C). However, although a
significant increase in RBF was observed after compound 21
infusion in males, this response was not dose dependent
(PDose0.05). This effect was completely abolished in the
presence of AT2R blockade with PD123319 (PGroup0.006;
Figure 1B).
Likewise in females, baseline RBF did not differ signifi-
cantly between the treatment groups (Table). In response to
vehicle infusion, RBF remained near baseline levels but
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increased significantly in response to compound 21 treatment
(PGroup0.0001; Figure 1E). RBF increased by 23.03.2%
from baseline in the presence of 300 ng/kg per minute of
compound 21 (P3000.001). However, unlike in males, the
renal vasodilatory response to compound 21 observed in
females was dose dependent (PDose0.0001). This in turn
resulted in a dose-dependent reduction in RVR as compared
with vehicle treatment (Figure 1F). Each of these effects in
females was abolished by coinfusion of PD123319
(PGroup0.0006 for RBF and 0.001 for RVR; Figure 1E and
1F). Notably, there was a trend for the magnitude of the effect
of compound 21 on RBF to be greater in females as compared
with males (PSex0.059). The reduction in RVR was also
significantly greater in the female compound 21-treated
versus the male compound 21-treated group (PSex0.04).
These sex differences were particularly evident at the
Table. Baseline Levels of Mean Arterial Pressure, Renal Hemodynamics, Urine Flow, and Urinary
Sodium Excretion
Group MAP, mm Hg RBF, mL/min/g GFR, mL/min/g UF, l/min/g UNaV, mol/min/g
Male vehicle 1195 3.80.2 1.30.1 6.31.5 0.30.1
Male compound 21 1173.0 4.00.1 1.50.1 5.20.5 0.20.04
Male compound 21PD123319 1224 3.80.2 1.30.2 7.03.9 0.60.5
Female vehicle 1163 3.30.2 1.40.05 8.51.6 0.60.2
Female compound 21 1185 3.50.2 1.70.1 8.92.6 0.50.2
Female compound 21PD123319 1123 3.80.3 1.40.2 8.61.3 0.50.2
MAP indicates mean arterial pressure; RBF, renal blood flow; GFR, glomerular filtration rate; UF, urine flow; and UNaV, urinary
sodium excretion. Data are presented as meanSEM and were analyzed using an ANOVA with Tukey post hoc tests. n6 to 10 per
group. All of the RBF, GFR, UF, and UNaV values are expressed per gram of left wet kidney weight.
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Figure 1. Percentage changes from
baseline for mean arterial pressure
(MAP), renal blood flow (RBF), and renal
vascular resistance (RVR) in male (A
through C) and female (D through F) rats
in response to 100 to 300 ng/kg per min-
ute of compound 21. Data are presented
as meanSEM and were analyzed using
repeated-measures ANOVA with Bonfer-
roni post hoc tests. *P0.05, **P0.01,
***P0.001 vs vehicle-treated rats;
†P0.05, ††P0.01, †††P0.001 vs
compound 21PD123319-treated rats.
n6 to 10 per group. All of the RBF and
RVR values are expressed per gram of
left wet kidney weight.
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highest dose of compound 21 administered (P3000.01 for
RBF and RVR).
Influence of Direct AT2R Stimulation on Renal
Excretory Function
Renal excretory function was also examined during the
baseline and 300 ng/kg per minute of compound 21 experi-
mental periods in a subset of animals. Baseline glomerular
filtration rate (GFR) was similar between the male and female
treatment groups (Table). In response to vehicle treatment,
we observed a time-dependent reduction in GFR. However,
in response to 300 ng/kg per minute of compound 21, a
similar reduction in GFR was observed in both the male and
female rats, which did not differ significantly from that
observed in the vehicle-treated groups (PGroup0.05; Figure
2A). Subsequently, the observed changes in RBF and GFR
resulted in a greater reduction in filtration fraction in response
to compound 21 as compared with vehicle treatment
(PGroup0.004; Figure 2B). This was not a sex-dependent
effect and was ameliorated by coinfusion of PD123319.
In terms of urine flow (UF) and urinary sodium excretion
(UNaV), baseline levels did not differ significantly between
the treatment groups of either sex (Table). In both males and
females, a time-dependent increase in UF, UNaV, and FENa
was observed in response to vehicle treatment (Figure 2C
through 2E). UF, UNaV, and FENa were also increased in
response to infusion of 300 ng/kg per minute of compound 21 in
males and females. However, this occurred to a significantly
greater extent than was observed in the vehicle-treated groups
(PGroup0.05 for UF and 0.005 for UNaV and FENa). The
magnitude of the UF, UNaV, and FENa responses to compound
21 was similar between the sexes (PSex*Group0.05) and was
abolished in both males and females by coinfusion of compound
21 and PD123319 (Figure 2C through 2E).
Discussion
The major finding observed in this study was that direct
AT2R stimulation using the AT2R agonist, compound 21,
induced renal vasodilation and natriuretic effects in both
normotensive male and female rats. The renal vasodilatory
effects of compound 21 were dose dependent in females only
and were observed to a greater extent in females than males
at higher concentrations of compound 21. These observations
support the conclusion that direct AT2R stimulation with
compound 21 has a sex-specific influence on renal function.
In addition, compound 21 administration caused similar
increases in sodium and water excretion in males and fe-
males. To the best of our knowledge, this is the first study that
has investigated the sex-specific influence of direct AT2R
stimulation on renal hemodynamics and excretory function.
In the past, investigations into the effects of AT2R stimu-
lation have been limited because of the restricted availability
of metabolically stable AT2R agonists.14 Recently, the highly
specific nonpeptide AT2R agonist, compound 21, has become
available. It is estimated that, because of its nonpeptide nature,
compound 21 has an approximate bioavailability of 20% to 30%
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Figure 2. Percentage changes from baseline for (A) glomerular filtration rate (GFR), (B) filtration fraction (FF), (C) urine flow (UF), (D)
sodium excretion (UNaV), and (E) fractional sodium excretion (FENa) in male (f) and female () rats in response to 300 ng/kg per min-
ute of compound 21. Data are presented as meanSEM and were analyzed using a 2-way ANOVA using the factors sex (PSex), group
(PGroup), and the interaction between sex and group (PInteraction). n5 to 7 per group. All of the values are expressed per gram of left
wet kidney weight.
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and a 4-hour half-life in rats.15 Moreover, compound 21 exhibits
a similar biological response to Ang II and the commonly used
peptide AT2R agonist, CGP42112, but with minimal affinity for
the AT1R.15 It is, therefore, widely becoming recognized as an
ideal research tool suitable for direct investigations into the
effects of AT2R stimulation.16
In the present study, the dose selection of compound 21
was based on our observations from previous studies where
we assessed the dose-dependent vascular effects of com-
pound 21 in conscious spontaneously hypertensive rats,
across a wide dose range.14 In the presence of AT1R block-
ade, acute administration of compound 21 lowered arterial
pressure at doses ranging from 50 to 300 ng/kg per minute.
This effect was completely abolished by coinfusion of
PD123319. This selectivity for the AT2R, however, appeared
to be lost at higher doses of compound 21 tested (1000 ng/kg
per minute), as indicated by increasing arterial pressure. Wan
et al15 also observed a similar bell-shaped dose-response
relationship in anesthetized spontaneously hypertensive rats.
In the current study, intravenous infusion of compound 21
had a marked influence on renal hemodynamic function. We
observed a significant increase in RBF in both male and
female rats. This renal vasodilatory response was also re-
flected by a significant reduction in RVR. In combination
with AT2R blockade using PD123319, these effects were
abolished, thereby supporting the role of the AT2R in these
responses. As we have discussed in detail previously, block-
ade of the AT1R is generally required to inhibit circulating
endogenous Ang II from exerting tonic AT1R-mediated
vasoconstriction for AT2R-mediated vasodilation to be man-
ifest.17 Remarkably, the increased renal vasodilatory response
to compound 21 in the present study was observed in the
absence of any AT1R blockade, demonstrating the ability of
compound 21 to directly modulate renal function.
At higher concentrations of the AT2R agonist, the renal
vasodilatory response was significantly different between the
sexes. At the highest dose of compound 21 administered,
females demonstrated a more pronounced increase in RBF than
males. In fact, in males the RBF response to graded infusion of
compound 21 was not dose dependent. This may indicate that, in
males, the peak receptor saturation response to compound 21
was reached at a lower dose than in females. In support of this
notion, a lower abundance of the AT2R has been identified
previously in the male versus female renal vasculature. Studies
examining angiotensin receptor expression in rodents have
reported AT2R expression in the glomeruli, afferent arterioles,
arcuate arteries, and medullary descending vasa recta,12,18,19 with
evidence of greater AT2R expression in the female vasculature.18
The sex-specific response to AT2R stimulation is also
consistent with our findings reported recently in normoten-
sive rats that the AT2R plays a more significant role in the
female versus male renal vasculature.13 In response to exog-
enous administration of Ang II, we previously observed
dose-dependent decreases in RBF in both males and females.
In the presence of AT2R blockade with PD123319, RBF was
further reduced in females alone, indicating a protective role
of the AT2R in females against the renal vasoconstrictor
effects of Ang II.13 Although we did not previously observe
a significant role for the AT2R in the male renal vasculature,
it should be recognized that examination of the effects of
AT2R blockade on renal function alone does not necessarily
reflect the potential for AT2R activation to directly modulate
renal function. As we have reviewed in detail previously,
whereas evidence suggests the AT2R may be constitutively
active, the permanent endogenous activity of the AT2R is
much lower than its activity during pharmacological stimu-
lation.20 Indeed, our present findings suggest that AT2R
stimulation may provide renoprotective effects in both sexes.
However, it must be considered when interpreting these
results that these experiments were performed in denervated
kidneys to avoid the potentially confounding influence of
changes in renal sympathetic activity on renal function.
In the current study, we also observed significant increases in
sodium and water excretion in response to AT2R stimulation
with compound 21 in both males and females. Recently, we
reported that the AT2R modulates sodium excretion in both
sexes. In male and female normotensive rats, blockade of the
AT2R was shown to blunt the pressure-natriuresis relationship,
suggesting that the AT2R enhances the natriuretic capacity of the
kidney.13 In the present study we provided further evidence that
supports these findings. AT2R stimulation by compound 21
significantly increased sodium and water excretion in both male
and female rats, an effect abolished by concomitant infusion of
compound 21 and PD123319. Moreover, the increase in UNaV
and UF was similar in the male and female AT2R agonist-treated
rats. Thus, AT2R stimulation appears to have similar effects on
sodium excretion between the sexes.
As we have discussed in detail previously,13 the natriuretic
action of the AT2R has been associated with NO-mediated
changes in renal hemodynamics and/or tubular sodium handling.
It is well documented that AT2R activation in the vasculature
stimulates bradykinin and NO and cGMP production, resulting
in vasodilation.7 This vasodilatory cascade has also been linked
to the inhibition of sodium transport in the renal tubules.21–23
Indeed, in addition to its localization in the renal vasculature
mentioned previously, AT2R expression has also been identified
in the renal tubules, particularly within proximal tubular
cells.19,24 Interestingly, despite the change in renal excretory
function in response to compound 21 in males and females, we
did not see any significant change in GFR at the highest
concentration of compound 21 in either sex. Given the major
increase in RBF, a significant reduction in filtration fraction was,
therefore, observed. The most likely explanation for this reduc-
tion in filtration fraction is that compound 21 has similar dilatory
effects on both the preglomerular and postglomerular arterioles.
This would result in increases in RBF, whereas GFR remains
unchanged. Alternatively, we cannot rule out the possibility that
AT2R stimulation has a marked influence on the glomerular
capillary ultrafiltration coefficient. Previous studies by Suzuki et
al25 have identified a role for the AT2R in the maintenance of
glomerular barrier function attributed to its presence on podo-
cytes. They showed that AT2R-mediated action enhances the
expression of slit diaphragm-associated molecules. It is, there-
fore, plausible that AT2R stimulation in our study resulted in
relaxation of podocytes, reducing the surface area available for
filtration. This reduction in ultrafiltration coefficient could coun-
terbalance any increase in glomerular capillary pressure induced
by AT2R stimulation, leading to the no change in GFR that we
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observed. Investigations into the exact localization of the angio-
tensin receptors in the glomerular vasculature could provide
further insight into these observations. Nonetheless, a change in
GFR does not appear to be a factor facilitating AT2R-induced
natriuresis. Rather, these collective observations suggest that the
renal tubule is the major site of action, and the increased
excretion of sodium in response to AT2R stimulation is attrib-
uted to an inhibition of tubular sodium reabsorption, independent
of AT2R-mediated changes in renal hemodynamics. This is
further supported by the increase in fractional excretion of
sodium in both the male and female compound 21–treated rats.
In terms of future studies, it would be of interest to
investigate the influence of direct pharmacological AT2R
stimulation on renal hemodynamic and excretory function in
hypertension-related models. As briefly mentioned previously,
in male spontaneously hypertensive rats, we have demonstrated
previously that compound 21 acutely evokes vasodepressor
responses during simultaneous AT1R blockade.14 However, the
long-term and sex-specific responses to direct AT2R stimulation
during hypertension in the presence and absence of combined
AT1R blockade have not been investigated previously. Recently,
Matavelli et al26 reported that compound 21, over 4 days,
reduced renal inflammation and increases renal NO-cGMP
levels in 2-kidney, 1-clip Goldblatt hypertensive rats, in the
absence of any reductions in arterial pressure.
In conclusion, we have shown in both male and female
normotensive rats that compound 21 produces renal vasodi-
latory and natriuretic effects via direct stimulation of the
AT2R, in the absence of AT1R blockade. Given its significant
influence on renal function, the AT2R may therefore repre-
sent a significant therapeutic target for the treatment of renal
and cardiovascular disease. Moreover, compound 21 should
be considered as an ideal therapeutic tool to further elucidate
the sex-specific potential of direct AT2R stimulation as a
target in the treatment of renal and cardiovascular disease.
Perspectives
Taken together, these findings strongly suggest a protective
role of the AT2R in the kidney and vasculature. The AT2R
appears to play a pivotal role in the regulation of renal
hemodynamics and excretory function, which is enhanced in
females. Future studies may therefore investigate the beneficial
effects of AT2R stimulation in hypertensive states and may
ultimately lead to the development of sex-specific therapies.
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